相关实验视频

Updated: Jun 28, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

线粒体-选择性滴定小分子接体向G-四重复结构用于人类结肠直肠癌治疗

Bo-Xin Zheng¹, Wei Long¹, Wende Zheng²

¹State Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong SAR 999077, China.

Journal of medicinal chemistry

|April 16, 2024

概括

研究人员开发了一种新型的小分子,该分子向线粒体和线粒体DNAG-四重复合体 (G4s),以增强癌症药物输送. 在临床前模型中,这种二性脂性联体体表现出显著的抗癌活性和抗瘤疗效.

科学领域:

生物化学生物化学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

线粒体是癌症和其他疾病的关键药物标.
人类线粒体DNA的G-四复合体 (G4s) 是小分子疗法的新兴目标.
目前针对线粒体的配体有限,通常使用trifenylphosphonium支架,而不是针对G4s.

研究的目的:

设计和合成一个新的小尺寸的,二化,脂友性联结体.
针对高线粒体膜潜力 (MMP) 和线粒体DNA G4s.
为了增强抗癌应用的药物输送.

主要方法:

合成一个新的dikacionic脂友性联结体.
评估与MMP和线粒体DNA G4s. 的联结体相互作用.
在HCT116癌细胞和HCT116瘤异种移植小鼠模型中评估抗癌活性.

主要成果:

这种连接体诱导了线粒体基因表达的显著变化.
它大大增加了活性氧物种 (ROS) 的产生,导致线粒体功能障碍,DNA损伤,细胞衰老和亡.
该配体在体内显示出高抗癌活性 (IC50 = 3.4 μM) 和显著的抗瘤疗效 (~70%的瘤体重减少).

结论:

一种新型的小尺寸二化脂性联体有效向MMP和线粒体DNAG4s.
这种连接体通过诱导线粒体功能障碍和亡,表现出强大的抗癌活性和抗瘤疗效.
这些发现突出了开发针对线粒体的抗癌药物的有希望的新策略.

更多相关视频

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Single-molecule Manipulation of G-quadruplexes by Magnetic Tweezers

Single-molecule Manipulation of G-quadruplexes by Magnetic Tweezers

Published on: September 19, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...